Sitagliptin and metformin (DrugBank: Metformin, Sitagliptin)
21 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 0 |
6 | Parkinson disease | 1 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
46 | Malignant rheumatoid arthritis | 0 |
49 | Systemic lupus erythematosus | 0 |
60 | Aplastic anemia | 0 |
67 | Polycystic kidney disease | 0 |
75 | Cushing disease | 0 |
77 | Growth hormone secreting pituitary adenoma | 0 |
81 | Congenital adrenal hyperplasia | 0 |
86 | Pulmonary arterial hypertension | 0 |
113 | Muscular dystrophy | 0 |
127 | Frontotemporal lobar degeneration | 0 |
158 | Tuberous sclerosis | 0 |
206 | Fragile X syndrome | 0 |
225 | Congenital nephrogenic diabetes insipidus | 0 |
233 | Wolfram syndrome | 1 |
265 | Lipodystrophy | 0 |
285 | Fanconi anemia | 0 |
299 | Cystic fibrosis | 0 |
301 | Macular dystrophy | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2000029465 | 2020-04-06 | 2020-02-02 | Comparison of effects of sitagliptin and metformin on motor function and cognitive function in patients with Parkinson's disease complicated with type 2 diabetes | Comparison of effects of sitagliptin and metformin on motor function and cognitive function in patients with Parkinson's disease complicated with type 2 diabetes | Type 2 Diabetes | Sitagliptin group:Sitagliptin 100mg/d for 52 weeks;metformin group:metformin 1000-1500mg/d for 52 weeks; | Peking Union Medical College Hospital | NULL | Pending | 18 | 75 | Both | Sitagliptin group:20;metformin group:20; | Phase 4 | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02882477 (ClinicalTrials.gov) | December 2016 | 17/7/2016 | Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy | Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy | Diabetes Mellitus;Iron Metabolism Disorders;Gastroduodenal Ulcer;Optic Atrophy;Sensorineural Hearing Loss;Platelet Dysfunction | Drug: Deferiprone;Drug: Acetylcysteine;Drug: Sitagliptin and Metformin | Hadassah Medical Organization | NULL | Not yet recruiting | 3 Years | N/A | Both | 20 | Phase 2;Phase 3 | Israel |